---
title: 'Toxicity and Patient Reported Quality of Life after PSMA-PET and mpMRT-Based
  Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year
  Follow-Up of the HypoFocal Phase II Trial'
date: '2023-10-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37784612/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231003180922&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Despite large boost volumes, the 2 years FU of the HypoFocal-Phase
  II trials shows no significantly increased GU and GU toxicities compared to baseline
  symptoms. Patients reported about a good QoL but increased bowel symptoms after
  2 years, particularly if treated with EBRT only. Implementation of PSMA-PET into
  focal dose escalated radiotherapy approaches appears safe and feasible. However,
  radioproctitis demands careful management. The current PSA values suggest a highly
  ...'
disable_comments: true
---
CONCLUSION: Despite large boost volumes, the 2 years FU of the HypoFocal-Phase II trials shows no significantly increased GU and GU toxicities compared to baseline symptoms. Patients reported about a good QoL but increased bowel symptoms after 2 years, particularly if treated with EBRT only. Implementation of PSMA-PET into focal dose escalated radiotherapy approaches appears safe and feasible. However, radioproctitis demands careful management. The current PSA values suggest a highly ...